Clinical Efficacy And Risk Factors Of First ¹³¹I Remnant Ablation In Patients With Differentiated Thyroid Carcinoma After Thyroidectomy

ObjectiveTo investigate the clinical efficacy and risk factors of first ¹³¹I remnant ablation in patients with differentiated thyroid carcinoma after thyroidectomy.MethodsFrom Jun 2017 to Dec 2018,a total of 94 patients（31 males,63females,age range 20-72 years）with differentiated thyroid carcinoma underwent first ¹³¹I remnant ablation after thyroidectomy in Henan Provincial People’s Hospital,were enrolled in this study.The clinical data such as age,sex,surgical operation methods and frequency,the interval between thyroidectomy and first ¹³¹I remnant ablation,lesion location,pathological type,residual thyroid weight,metastatic tumors visible to naked eye,lymph node metastasis,TSH and TgAb levels before ¹³¹I treatment,therapeutic dose of ¹³¹I,the presence of Hashimoto’s thyroiditis,AJCC staging and risk of recurrence were collected and classified.Then,according to the 2015American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer,the clinical efficacy and risk factors of first¹³¹I remnant ablation in patients with differentiated thyroid carcinoma after thyroidectomy was investigated.Results（1）68/94 patients（72.34%）had achieved successful thyroid remnant ablation after first dose of¹³¹I.（2）Univariate analysis showed the clinical efficacy of first¹³¹I remnant ablation was not relevant to the risk factors such as age,sex,surgical operation methods and frequency,the interval between thyroidectomy and first¹³¹I remnant ablation,lesion location,pathological type,residual thyroid weight,metastatic tumors visible to naked eye,lymph node metastasis,TSH and TgAb levels before¹³¹I treatment,therapeutic dose of¹³¹I.（3）The success rate in patients with the<10ng/mL of Tg level,total resection surgery,no distant metastasis and low and medium risk factors was significantly higher than that of patients with the≥10ng/mL of Tg level,sub-total resection surgery,distant metastasis and high risk factors（P<0.05）.Conclusion（1）The¹³¹I remnant ablation is a very safe and effective therapy for patients with differentiated thyroid carcinoma after thyroidectomy.In this retrospective study（n=94）,the success rate of first ¹³¹I remnant ablation was determined to be 72.34%.（2）The Tg level,surgical operation methods,presence of distant metastasis or risk of recurrence before first ¹³¹I remnant ablation is a dependent of influential factors of clinical efficacy of first ¹³¹I remnant ablation in patients with differentiated thyroid carcinoma after thyroidectomy.